-
1
-
-
3042516892
-
The clinical and epidemiological burden of chronic lymphocytic leukaemia
-
Redaelli A, Laskin BL, Stephens JM et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care 13, 279-1267 (2004).
-
(2004)
Eur. J. Cancer Care
, vol.13
, pp. 279-1267
-
-
Redaelli, A.1
Laskin, B.L.2
Stephens, J.M.3
-
2
-
-
0037616996
-
-
National Cancer Institute,BethesdaMD, USA
-
Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review 1975-2001. National Cancer Institute, Bethesda, MD, USA (2001).
-
(2001)
SEER Cancer Statistics Review 1975- 2001
-
-
Ries, L.A.G.1
Eisner, M.P.2
Kosary, C.L.3
-
3
-
-
0019427092
-
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
-
Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206 (1981).
-
(1981)
Cancer
, vol.48
, pp. 198-206
-
-
Binet, J.L.1
Auquier, A.2
Dighiero, G.3
-
4
-
-
0016740933
-
Clinical staging of chronic lymphocytic leukemia
-
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Paternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234 (1975).
-
(1975)
Blood
, vol.46
, pp. 219-234
-
-
Rai, K.R.1
Sawitsky, A.2
Cronkite, E.P.3
Chanana, A.D.4
Levy, R.N.5
Paternack, B.S.6
-
5
-
-
15244342190
-
Chronic lymphocytic leukemia: Novel prognostic factors and their relevance for risk-adapted therapeutic strategies
-
Montiilo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90, 391-399 (2005).
-
(2005)
Haematologica
, vol.90
, pp. 391-399
-
-
Montiilo, M.1
Hamblin, T.2
Hallek, M.3
Montserrat, E.4
Morra, E.5
-
6
-
-
0034727833
-
Genomic aberrations and survival in chronic lymphocytic leukemia
-
DOI 10.1056/NEJM200012283432602
-
Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910-1916 (2000). (Pubitemid 32064784)
-
(2000)
New England Journal of Medicine
, vol.343
, Issue.26
, pp. 1910-1916
-
-
Dohner, H.1
Stilgenbauer, S.2
Benner, A.3
Leupolt, E.4
Krober, A.5
Bullinger, L.6
Dohner, K.7
Bentz, M.8
Lichter, P.9
-
7
-
-
0344729013
-
Chlorambucil in indolent chronic lymphocytic leukemia
-
Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. J. Med. 338, 1506-1514 (1998).
-
(1998)
N. Engl. J. Med.
, vol.338
, pp. 1506-1514
-
-
Dighiero, G.1
Maloum, K.2
Desablens, B.3
-
8
-
-
0033583824
-
Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials
-
CLL Trialists Collaborative Group
-
CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst. 91, 861-868 (1999).
-
(1999)
J. Natl Cancer Inst.
, vol.91
, pp. 861-868
-
-
-
9
-
-
70350720141
-
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
-
German CLL Study Group (GCLLSG)
-
Eichhorst BF, Busch R, Stilgenbauer S et al. German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382-3391 (2009).
-
(2009)
Blood
, vol.114
, Issue.16
, pp. 3382-3391
-
-
Eichhorst, B.F.1
Busch, R.2
Stilgenbauer, S.3
-
10
-
-
0036273331
-
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
-
Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16, 1015-1027 (2002).
-
(2002)
Leukemia
, vol.16
, pp. 1015-1027
-
-
Robak, T.1
Kasznicki, M.2
-
11
-
-
0842322870
-
High dose chlorambucil in the treatment of lymphoid malignancies
-
Nicolle A, Proctor SJ, Summerfield GP. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk. Lymphoma 45, 271-275 (2004).
-
(2004)
Leuk. Lymphoma
, vol.45
, pp. 271-275
-
-
Nicolle, A.1
Proctor, S.J.2
Summerfield, G.P.3
-
12
-
-
0034649696
-
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
-
Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
-
(2000)
N. Engl. J. Med.
, vol.343
, pp. 1750-1757
-
-
Rai, K.R.1
Peterson, B.L.2
Appelbaum, F.R.3
-
13
-
-
0034667537
-
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
-
Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96, 2723-2729 (2000).
-
(2000)
Blood
, vol.96
, pp. 2723-2729
-
-
Robak, T.1
Blonski, J.Z.2
Kasznicki, M.3
-
14
-
-
63449116519
-
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases
-
Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14(3), 1183-1226 (2009).
-
(2009)
Molecules
, vol.14
, Issue.3
, pp. 1183-1226
-
-
Robak, T.1
Korycka, A.2
Lech-Maranda, E.3
Robak, P.4
-
15
-
-
26944435896
-
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)
-
Robak T, Blonski JZ, Kasznicki M et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med. Sci. Monit. 11, 71-79 (2005).
-
(2005)
Med. Sci. Monit.
, vol.11
, pp. 71-79
-
-
Robak, T.1
Blonski, J.Z.2
Kasznicki, M.3
-
16
-
-
0035889147
-
Randomized comparison of fludarabine,CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
-
Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98, 2319-2325 (2001).
-
(2001)
Blood
, vol.98
, pp. 2319-2325
-
-
Leporrier, M.1
Chevret, S.2
Cazin, B.3
-
17
-
-
0032830965
-
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
-
Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94, 2836-2843 (1999).
-
(1999)
Blood
, vol.94
, pp. 2836-2843
-
-
Bellosillo, B.1
Villamor, N.2
Colomer, D.3
Pons, G.4
Montserrat, E.5
Gil, J.6
-
18
-
-
0035179950
-
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited byfludarabine and clofarabine
-
Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited byfludarabine and clofarabine. Clin. Cancer Res. 7(11), 3580-3589 (2001).
-
(2001)
Clin. Cancer Res.
, vol.7
, Issue.11
, pp. 3580-3589
-
-
Yamauchi, T.1
Nowak, B.J.2
Keating, M.J.3
Plunkett, W.4
-
19
-
-
0035282055
-
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
-
O'Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 1414-1420 (2001).
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1414-1420
-
-
O'Brien, S.M.1
Kantarjian, H.M.2
Cortes, J.3
-
20
-
-
31544434508
-
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
-
Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107, 885-891 (2006).
-
(2006)
Blood
, vol.107
, pp. 885-891
-
-
Eichhorst, B.F.1
Busch, R.2
Hopfinger, G.3
-
21
-
-
33947541773
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
-
Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25, 793-798 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 793-798
-
-
Flinn, I.W.1
Neuberg, D.S.2
Grever, M.R.3
-
22
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial
-
Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370, 230-239 (2007).
-
(2007)
Lancet
, vol.370
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
-
23
-
-
33745942111
-
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)
-
Robak T, Blonski JZ, Gora-Tybor et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108, 473-479 (2006).
-
(2006)
Blood
, vol.108
, pp. 473-479
-
-
Robak, T.1
Gora-Tybor, B.J.2
-
24
-
-
0037214931
-
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
-
DOI 10.1002/cncr.11000
-
Montillo M, Tedeschi A, O'Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97, 114-120 (2003). (Pubitemid 36033870)
-
(2003)
Cancer
, vol.97
, Issue.1
, pp. 114-120
-
-
Montillo, M.1
Tedeschi, A.2
O'Brien, S.3
Di Raimondo, F.4
Lerner, S.5
Ferrajoli, A.6
Morra, E.7
Keating, M.J.8
-
25
-
-
0036430207
-
Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia
-
Robak T, B?o?ski JZ, Kasznicki M et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol. J. 3, 244-250 (2002).
-
(2002)
Hematol. J.
, vol.3
, pp. 244-250
-
-
Robak, T.1
Boski, J.Z.2
Kasznicki, M.3
-
26
-
-
58949092546
-
Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: Report from the Polish Adult Leukemia Group
-
Robak T, Blonski JZ, Wawrzyniak E et al. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer 115, 94-100 (2009).
-
(2009)
Cancer
, vol.115
, pp. 94-100
-
-
Robak, T.1
Blonski, J.Z.2
Wawrzyniak, E.3
-
27
-
-
77951628255
-
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: A Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
-
Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J. Clin. Oncol. 28, 1861-1869 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1861-1869
-
-
Robak, T.1
Jamroziak, K.2
Gora-Tybor, J.3
-
28
-
-
0038514130
-
Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia
-
Weiss MA, Maslak, P, Jurcic JG et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21, 1278-1284 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 1278-1284
-
-
Weiss, M.A.1
Maslak, P.2
Jurcic, J.G.3
-
29
-
-
72149089893
-
Current and emerging treatments for chronic lymphocytic leukaemia
-
Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 69, 2415-2449 (2009).
-
(2009)
Drugs
, vol.69
, pp. 2415-2449
-
-
Robak, T.1
Jamroziak, K.2
Robak, P.3
-
30
-
-
34249655671
-
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
-
Alinari L, Lapalombella R, Andritsos L et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26, 3644-3653 (2007).
-
(2007)
Oncogene
, vol.26
, pp. 3644-3653
-
-
Alinari, L.1
Lapalombella, R.2
Andritsos, L.3
-
31
-
-
48849109653
-
Alemtuzumab for B-cell chronic lymphocytic leukemia
-
Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 8(7), 1033-1051 (2008).
-
(2008)
Expert Rev. Anticancer Ther.
, vol.8
, Issue.7
, pp. 1033-1051
-
-
Robak, T.1
-
33
-
-
16544389341
-
The biology of CD20 and its potential as a target for mAb therapy
-
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140-174 (2005).
-
(2005)
Curr. Dir. Autoimmun.
, vol.8
, pp. 140-174
-
-
Cragg, M.S.1
Walshe, C.A.2
Ivanov, A.O.3
Glennie, M.J.4
-
34
-
-
0142180086
-
Store-operated cation entry mediated by CD20 in membrane rafts
-
Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 278, 42427-42434 (2003).
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 42427-42434
-
-
Li, H.1
Ayer, L.M.2
Lytton, J.3
Deans, J.P.4
-
35
-
-
0038446696
-
Circulating CD20 is detectable in the plasma of patients with chromic lymphocytic leukemia and its prognostic significance
-
Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chromic lymphocytic leukemia and its prognostic significance. Blood 101, 2507-2513 (2003).
-
(2003)
Blood
, vol.101
, pp. 2507-2513
-
-
Manshouri, T.1
Do, K.A.2
Wang, X.3
-
36
-
-
0034951864
-
Mechanism of action of rituximab
-
Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 12(Suppl. 2), 1-4 (2001).
-
(2001)
Anticancer Drugs
, vol.12
, Issue.SUPPL. 2
, pp. 1-4
-
-
Maloney, D.G.1
-
37
-
-
0028057250
-
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
-
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
-
(1994)
Blood
, vol.83
, pp. 435-445
-
-
Reff, M.E.1
Carner, K.2
Chambers, K.S.3
-
38
-
-
0034660092
-
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis
-
Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95, 3900-3908 (2000).
-
(2000)
Blood
, vol.95
, pp. 3900-3908
-
-
Golay, J.1
Zaffaroni, L.2
Vaccari, T.3
-
39
-
-
0037306946
-
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
-
Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045-1052 (2003).
-
(2003)
Blood
, vol.101
, pp. 1045-1052
-
-
Cragg, M.S.1
Morgan, S.M.2
Chan, H.T.3
-
40
-
-
0037306893
-
In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas
-
Manches O, Lui G, Chapero L et al. In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood 101, 949-954 (2003).
-
(2003)
Blood
, vol.101
, pp. 949-954
-
-
Manches, O.1
Lui, G.2
Chapero, L.3
-
41
-
-
0032030699
-
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
-
Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644-1652 (1998).
-
(1998)
Blood
, vol.91
, pp. 1644-1652
-
-
Shan, D.1
Ledbetter, J.A.2
Press, O.W.3
-
42
-
-
0034104375
-
Signaling events involved in anti-CD20 induced apoptosis of malignant human B-cells
-
Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20 induced apoptosis of malignant human B-cells. Cancer Immunol. Immunother. 48, 673-683 (2000).
-
(2000)
Cancer Immunol. Immunother.
, vol.48
, pp. 673-683
-
-
Shan, D.1
Ledbetter, J.A.2
Press, O.W.3
-
43
-
-
12744279711
-
Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells
-
Smolewski P, Szmigielska-Kap?on A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 40, 87-100 (2005).
-
(2005)
Leuk. Lymphoma
, vol.40
, pp. 87-100
-
-
Smolewski, P.1
Szmigielska-Kapon, A.2
Cebula, B.3
-
44
-
-
0036154263
-
Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement and caspases
-
Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 87, 33-43 (2002).
-
(2002)
Haematologica
, vol.87
, pp. 33-43
-
-
Chow, K.U.1
Sommerlad, W.D.2
Boehrer, S.3
-
45
-
-
0033794618
-
Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxlyline and rituximab
-
Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxlyline and rituximab. Anticancer Res. 20, 2961-2966 (2000).
-
(2000)
Anticancer Res.
, vol.20
, pp. 2961-2966
-
-
Alas, S.1
Bonavida, B.2
Emmanouilides, C.3
-
46
-
-
0034796371
-
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone
-
Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 11, 800-809 (2001).
-
(2001)
Br. J. Haematol.
, vol.11
, pp. 800-809
-
-
Di Gaetano, N.1
Xiao, Y.2
Erba, E.3
-
47
-
-
0036340530
-
In vitro studies with bendamustine: Enhanced activity in combination with rituximab
-
Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin. Oncol. 29(4 Suppl. 13), 12-14 (2002).
-
(2002)
Semin. Oncol.
, vol.29
, Issue.4 SUPPL. 13
, pp. 12-14
-
-
Rummel, M.J.1
Chow, K.U.2
Hoelzer, D.3
Mitrou, P.S.4
Weidmann, E.5
-
48
-
-
0034890639
-
Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells
-
Shan D, Gopal AK, Press OW. Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin. Cancer Res. 7, 2490-2495 (2001).
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 2490-2495
-
-
Shan, D.1
Gopal, A.K.2
Press, O.W.3
-
49
-
-
0030800131
-
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
-
Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12, 177-186 (1997).
-
(1997)
Cancer Biother. Radiopharm.
, vol.12
, pp. 177-186
-
-
Demidem, A.1
Lam, T.2
Alas, S.3
-
50
-
-
0034467186
-
Chemotherapy sensitization by rituximab: Experimental and clinical evidence
-
Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin. Oncol. 27(Suppl. 12), 30-36 (2000).
-
(2000)
Semin. Oncol.
, vol.27
, Issue.SUPPL. 12
, pp. 30-36
-
-
Wilson, W.H.1
-
51
-
-
7144250528
-
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
-
The IDEC-C2B8 Study Group
-
Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann. Oncol. 9, 527-534 (1998).
-
(1998)
Ann. Oncol.
, vol.9
, pp. 527-534
-
-
Tobinai, K.1
Kobayashi, Y.2
Narabayashi, M.3
-
52
-
-
0035871441
-
Rituximab dose-escalation trial in chronic lymphocytic leukemia
-
O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 2165-2170 (2001). (Pubitemid 32366970)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.8
, pp. 2165-2170
-
-
O'Brien, S.M.1
Kantarjian, H.2
Thomas, D.A.3
Giles, F.J.4
Freireich, E.J.5
Cortes, J.6
Lerner, S.7
Keating, M.J.8
-
53
-
-
0035871445
-
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
-
Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19, 2153-2164 (2001).
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 2153-2164
-
-
Byrd, J.C.1
Murphy, T.2
Howard, R.S.3
-
54
-
-
0034043849
-
Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab
-
Herold M, Schulze A, Hartwig K, Anger G. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab. Ann. Hematol. 79, 332-335 (2000).
-
(2000)
Ann. Hematol.
, vol.79
, pp. 332-335
-
-
Herold, M.1
Schulze, A.2
Hartwig, K.3
Anger, G.4
-
55
-
-
0036757311
-
Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study
-
Itala M, Geisler CH, Kimby E et al. Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol. 69, 129-134 (2002).
-
(2002)
Eur. J. Haematol.
, vol.69
, pp. 129-134
-
-
Itala, M.1
Geisler, C.H.2
Kimby, E.3
-
56
-
-
0036839469
-
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
-
Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100, 3115-3120 (2002).
-
(2002)
Blood
, vol.100
, pp. 3115-3120
-
-
Schulz, H.1
Klein, S.K.2
Rehwald, U.3
-
57
-
-
0037220152
-
Randomized Phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712)
-
Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 101, 6-14 (2003).
-
(2003)
Blood
, vol.101
, pp. 6-14
-
-
Byrd, J.C.1
Peterson, B.L.2
Morrison, V.A.3
-
58
-
-
29144449249
-
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia
-
Del Poeta G, DelPrincipe MI, Consalvo MA et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer 104, 2743-2752 (2005).
-
(2005)
Cancer
, vol.104
, pp. 2743-2752
-
-
Del Poeta, G.1
Delprincipe, M.I.2
Consalvo, M.A.3
-
59
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective analysis of CALGB 9712 and CALGB 9011
-
Byrd J, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53 (2005).
-
(2005)
Blood
, vol.105
, pp. 49-53
-
-
Byrd, J.1
Rai, K.2
Peterson, B.L.3
-
60
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia
-
Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
-
61
-
-
23044501404
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.12.516
-
Wierda W, O'Brien, S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078 (2005). (Pubitemid 46211312)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4070-4078
-
-
Wierda, W.1
O'Brien, S.2
Wen, S.3
Faderl, S.4
Garcia-Manero, G.5
Thomas, D.6
Do, K.-A.7
Cortes, J.8
Koller, C.9
Beran, M.10
Ferrajoli, A.11
Giles, F.12
Lerner, S.13
Albitar, M.14
Kantarjian, H.15
Keating, M.16
-
62
-
-
51649093353
-
Long term results of the fludarabine, cyclophosphamide and rituximab as initial therapy of chric lymphocytic leukemia
-
Tam CS, O'Brien S Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab as initial therapy of chric lymphocytic leukemia. Blood 112, 975-980 (2008).
-
(2008)
Blood
, vol.112
, pp. 975-980
-
-
Tam, C.S.1
O'Brien Wierda, S.W.2
-
63
-
-
76949091824
-
First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase iii trial on behalf of an international group of investigators and the german cll study group
-
Abstract 535
-
Hallek M, Fingerle-Rowson G, Fink AM et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized Phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. Blood 114 (2009) (Abstract 535).
-
(2009)
Blood
, vol.114
-
-
Hallek, M.1
Fingerle-Rowson, G.2
Fink, A.M.3
-
64
-
-
70350259810
-
Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - A prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial
-
Abstract 326
-
Boettcher S, Fischer K, Stilgenbauer S et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 326).
-
(2008)
Blood (ASH Annual Meeting Abstracts)
, vol.112
-
-
Boettcher, S.1
Fischer, K.2
Stilgenbauer, S.3
-
65
-
-
77950478885
-
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia
-
Robak T, Dmoszynska A, Solal-Celigny A et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1756-1765 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1756-1765
-
-
Robak, T.1
Dmoszynska, A.2
Solal-Celigny, A.3
-
66
-
-
76949094333
-
FC-g receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone
-
Abstract 2338
-
Dornan D, Spleiss O, Yeh R-F T et al. FC-g receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 2338).
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
-
-
Dornan, D.1
Spleiss, O.2
Yeh -F, R.T.3
-
67
-
-
77958050280
-
Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone
-
Abstract 1368
-
Robak T, Aultman R, Oertel SHK et al. Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 1368).
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
-
-
Robak, T.1
Aultman, R.2
Oertel, S.H.K.3
-
68
-
-
59149090791
-
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia
-
Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 498-503 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 498-503
-
-
Foon, K.A.1
Boyiadzis, M.2
Land, S.R.3
-
69
-
-
59449110380
-
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
-
Tsimberidou AM, Tam C, Abruzzo LV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115, 373-380 (2009).
-
(2009)
Cancer
, vol.115
, pp. 373-380
-
-
Tsimberidou, A.M.1
Tam, C.2
Abruzzo, L.V.3
-
70
-
-
77649184591
-
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years
-
Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk. Res. 34, 284-228 (2010).
-
(2010)
Leuk. Res.
, vol.34
, pp. 284-228
-
-
Faderl, S.1
Wierda, W.2
O'Brien, S.3
Ferrajoli, A.4
Lerner, S.5
Keating, M.J.6
-
71
-
-
74549145611
-
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia
-
Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4578-4584 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4578-4584
-
-
Bosch, F.1
Abrisqueta, P.2
Villamor, N.3
-
72
-
-
77950546050
-
NCRI CLL201 Trial: A randomized Phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
-
Abstract 752
-
Hillmen P, Pcock C, Cohen D et al. NCRI CLL201 Trial: a randomized Phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood 110, 231a (2007) (Abstract 752).
-
(2007)
Blood
, vol.110
, Issue.231
-
-
Hillmen, P.1
Pcock, C.2
Cohen, D.3
-
73
-
-
40449108219
-
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
-
DOI 10.2174/156800908783769319
-
Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr. Cancer Drug Targets. 8, 156-171 (2008). (Pubitemid 351347252)
-
(2008)
Current Cancer Drug Targets
, vol.8
, Issue.2
, pp. 156-171
-
-
Robak, T.1
-
74
-
-
38049094162
-
Combined cyclophosphamide fludarabine alemtuzumab and rituximab (CFAR) an active regimen for heavily treated patients with CLL
-
Abstract 31
-
Wierda WG, O'Brien SM, Faderl SH et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108, 14a (2006) (Abstract 31).
-
(2006)
Blood
, vol.108
, Issue.14 A
-
-
Wierda, W.G.1
O'Brien, S.M.2
Faderl, S.H.3
-
75
-
-
38949180269
-
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
-
Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111, 1594-1602 (2008).
-
(2008)
Blood
, vol.111
, pp. 1594-1602
-
-
Pathan, N.I.1
Chu, P.2
Hariharan, K.3
Cheney, C.4
Molina, A.5
Byrd, J.6
-
76
-
-
77449133613
-
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
-
Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115, 489-495 (2010).
-
(2010)
Blood
, vol.115
, pp. 489-495
-
-
Byrd, J.C.1
Kipps, T.J.2
Flinn, I.W.3
-
77
-
-
33846258434
-
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
-
Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
-
(2007)
Blood
, vol.109
, pp. 405-411
-
-
Kay, N.E.1
Geyer, S.M.2
Call, T.G.3
-
78
-
-
34249042684
-
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
-
Shanafelt TD, Lin T, Geyer SM et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109, 2291-2298 (2007).
-
(2007)
Cancer
, vol.109
, pp. 2291-2298
-
-
Shanafelt, T.D.1
Lin, T.2
Geyer, S.M.3
-
79
-
-
33645732715
-
Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia
-
Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 24, 1575-1581 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1575-1581
-
-
Lamanna, N.1
Kalaycio, M.2
Maslak, P.3
-
80
-
-
33749600951
-
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
-
Robak T, Smolewski P, Cebula B et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 107, 1542-1550 (2006).
-
(2006)
Cancer
, vol.107
, pp. 1542-1550
-
-
Robak, T.1
Smolewski, P.2
Cebula, B.3
-
81
-
-
34447326480
-
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
-
Robak T, Smolewski P, Cebula B et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol. 79, 107-113 (2007).
-
(2007)
Eur. J. Haematol.
, vol.79
, pp. 107-113
-
-
Robak, T.1
Smolewski, P.2
Cebula, B.3
-
82
-
-
70350132633
-
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
-
Castro JE, James DF, Sandoval-Sus JD et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 23, 1779-1789 (2009).
-
(2009)
Leukemia
, vol.23
, pp. 1779-1789
-
-
Castro, J.E.1
James, D.F.2
Sandoval-Sus, J.D.3
-
83
-
-
56249095457
-
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
-
Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22, 2048-2053 (2008).
-
(2008)
Leukemia
, vol.22
, pp. 2048-2053
-
-
Castro, J.E.1
Sandoval-Sus, J.D.2
Bole, J.3
Rassenti, L.4
Kipps, T.J.5
-
84
-
-
37149029392
-
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
-
Bowen DA, Call TG, Jenkins GD et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk. Lymphoma 48, 2412-2417 (2007).
-
(2007)
Leuk. Lymphoma
, vol.48
, pp. 2412-2417
-
-
Bowen, D.A.1
Call, T.G.2
Jenkins, G.D.3
-
85
-
-
0036154263
-
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases
-
Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87, 33-43 (2002).
-
(2002)
Haematologica
, vol.87
, pp. 33-43
-
-
Chow, K.U.1
Sommerlad, W.D.2
Boehrer, S.3
-
86
-
-
64349123114
-
Bendamustine in the treatment of chronic lymphocytic leukemia
-
Knauf W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 9(2), 165-174 (2009).
-
(2009)
Expert Rev. Anticancer Ther.
, vol.9
, Issue.2
, pp. 165-174
-
-
Knauf, W.1
-
87
-
-
65749110753
-
Bendamustine in combination with rituximab (BR)for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre Phase II trial of the German CLL Study Group (GCLLSG)
-
Abstract
-
Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood 112, 330 (2008) (Abstract).
-
(2008)
Blood
, vol.112
, pp. 330
-
-
Fischer, K.1
Stilgenbauer, S.2
Schweighofer, C.D.3
-
88
-
-
77950321929
-
Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter Phase II trial of the German CLL Study Group (GCLLSG)
-
Abstract 205
-
Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG). Blood 114, 89 (2009) (Abstract 205).
-
(2009)
Blood
, vol.114
, pp. 89
-
-
Fischer, K.1
Cramer, P.2
Stilgenbauer, S.3
-
89
-
-
0038724252
-
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
-
Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101, 3413-3415 (2003).
-
(2003)
Blood
, vol.101
, pp. 3413-3415
-
-
Faderl, S.1
Thomas, D.A.2
O'Brien, S.3
-
90
-
-
8644274039
-
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
-
Nabhan C, Patton D, Gordon LI et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk. Lymphoma 45, 2269-2273 (2004).
-
(2004)
Leuk. Lymphoma
, vol.45
, pp. 2269-2273
-
-
Nabhan, C.1
Patton, D.2
Gordon, L.I.3
-
91
-
-
77952573871
-
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence
-
Faderl S, Ferrajoli A, Wierda W et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10), 2360-2365 (2010).
-
(2010)
Cancer
, vol.116
, pp. 2360-2365
-
-
Faderl, S.1
Ferrajoli, A.2
Wierda, W.3
-
92
-
-
77954659957
-
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy
-
Ysebaert L, Gross E, Kühlein E et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 24, 1310-1316 (2010).
-
(2010)
Leukemia
, vol.24
, pp. 1310-1316
-
-
Ysebaert, L.1
Gross, E.2
Kühlein, E.3
-
93
-
-
33645982603
-
Infectious complications of chronic lymphocytic leukemia
-
Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin. Oncol. 33, 240-249 (2006).
-
(2006)
Semin. Oncol.
, vol.33
, pp. 240-249
-
-
Wadhwa, P.D.1
Morrison, V.A.2
-
94
-
-
77956413908
-
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 Phase III randomized intergroup study
-
van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J. Clin. Oncol. 28, 2853-2858 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2853-2858
-
-
Van Oers, M.H.1
Van Glabbeke, M.2
Giurgea, L.3
-
95
-
-
67949094458
-
Novel drugs for chronic lymphoid leukemias: Mechanism of action and therapeutic activity
-
Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr. Med. Chem. 16, 2212-2234 (2009).
-
(2009)
Curr. Med. Chem.
, vol.16
, pp. 2212-2234
-
-
Robak, T.1
-
96
-
-
38949185742
-
Safety and efficacy ofofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia A Phase I-II study
-
Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy ofofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A Phase I-II study. Blood 11, 1094-1100 (2008).
-
(2008)
Blood
, vol.11
, pp. 1094-1100
-
-
Coiffier, B.1
Lepretre, S.2
Pedersen, L.M.3
-
97
-
-
77950502126
-
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
-
Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1749-1755 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1749-1755
-
-
Wierda, W.G.1
Kipps, T.J.2
Mayer, J.3
-
98
-
-
70449603373
-
GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo
-
Abstract 2348
-
Umana P, Moessner E, Bruenker P et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood 110, 694a (2007) (Abstract 2348).
-
(2007)
Blood
, vol.110
-
-
Umana, P.1
Moessner, E.2
Bruenker, P.3
-
99
-
-
67649575638
-
A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease
-
Abstract 234
-
Salles GA, Morschhauser F, Cartron G et al. A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 112, 93 (2008) (Abstract 234).
-
(2008)
Blood
, vol.112
, pp. 93
-
-
Salles, G.A.1
Morschhauser, F.2
Cartron, G.3
-
100
-
-
67650657179
-
GA-101, a third-generation, humanized and glyco-engineered anti CD20 mAb for the treatment of B-cell lymphoid malignancies
-
Website
-
Robak T. GA-101, a third-generation, humanized and glyco-engineered anti CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin. Investig. Drugs 10, 588-596 (2009). Website
-
(2009)
Curr. Opin. Investig. Drugs
, vol.10
, pp. 588-596
-
-
Robak, T.1
-
101
-
-
77958068175
-
-
Biogen Idec This study has been terminated. Received: 19 October last updated: 12 August 2010 Lumiliximab with Fludarabine Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)
-
Biogen Idec. ClinicalTrials.gov identifier: NCT00391066. Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID). This study has been terminated. Received: 19 October 2006; last updated: 12 August 2010 http://clinicaltrials.gov
-
(2006)
ClinicalTrials.gov Identifier: NCT00391066
-
-
|